KR20220012903A - 알코올-유발성 피부 안면홍조의 치료 및 완화를 위한 조성물 및 방법 - Google Patents

알코올-유발성 피부 안면홍조의 치료 및 완화를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20220012903A
KR20220012903A KR1020217042000A KR20217042000A KR20220012903A KR 20220012903 A KR20220012903 A KR 20220012903A KR 1020217042000 A KR1020217042000 A KR 1020217042000A KR 20217042000 A KR20217042000 A KR 20217042000A KR 20220012903 A KR20220012903 A KR 20220012903A
Authority
KR
South Korea
Prior art keywords
subject
pharmaceutical composition
aldh2
alcohol
acetaldehyde
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217042000A
Other languages
English (en)
Korean (ko)
Inventor
에드워드 케이. 와이. 정
Original Assignee
이케이와이제이 컨설팅 투 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이케이와이제이 컨설팅 투 엘엘씨 filed Critical 이케이와이제이 컨설팅 투 엘엘씨
Publication of KR20220012903A publication Critical patent/KR20220012903A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020217042000A 2019-05-23 2020-05-22 알코올-유발성 피부 안면홍조의 치료 및 완화를 위한 조성물 및 방법 Withdrawn KR20220012903A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852000P 2019-05-23 2019-05-23
US62/852,000 2019-05-23
PCT/US2020/034273 WO2020237172A1 (en) 2019-05-23 2020-05-22 Compositions and methods for the treatment and mitigation of alcohol-induced skin flushing

Publications (1)

Publication Number Publication Date
KR20220012903A true KR20220012903A (ko) 2022-02-04

Family

ID=73458156

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217042000A Withdrawn KR20220012903A (ko) 2019-05-23 2020-05-22 알코올-유발성 피부 안면홍조의 치료 및 완화를 위한 조성물 및 방법

Country Status (7)

Country Link
US (1) US20220226286A1 (cg-RX-API-DMAC7.html)
EP (1) EP3973030A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022536408A (cg-RX-API-DMAC7.html)
KR (1) KR20220012903A (cg-RX-API-DMAC7.html)
CN (2) CN114144493A (cg-RX-API-DMAC7.html)
TW (1) TW202110437A (cg-RX-API-DMAC7.html)
WO (1) WO2020237172A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240069129A (ko) 2022-11-11 2024-05-20 대한민국(질병관리청 국립보건연구원장) 이상지질혈증 예측 또는 진단용 snp 마커 및 이의 용도
KR20240074388A (ko) 2022-11-21 2024-05-28 대한민국(질병관리청 국립보건연구원장) 당뇨병 예측 또는 진단용 hectd4 snp 마커 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6468319A (en) * 1987-09-09 1989-03-14 Nonogawa Shoji Yk Anti-inflammatory
JPH01287035A (ja) * 1988-05-13 1989-11-17 Sanwa Kagaku Kenkyusho Co Ltd 薬物並びにアルコール性中毒の予防剤とその治療剤
TW271400B (cg-RX-API-DMAC7.html) * 1992-07-30 1996-03-01 Pfizer
IT1306133B1 (it) * 1999-04-22 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina ed un inositolfosfato, utilequale integratore dietetico o medicamento.
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
US20110053999A1 (en) * 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
ATE554663T1 (de) * 2005-07-29 2012-05-15 Tima Foundation Zusammensetzung zur steuerung des alkohol metabolismus und zur reduktion des risikos von alkoholbedingten krankheiten
WO2008112164A2 (en) * 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
JP2011051942A (ja) * 2009-09-03 2011-03-17 Glovia:Kk 認知症治療薬
CN102549171A (zh) * 2009-10-07 2012-07-04 学校法人武库川学院 基因型的判断方法
PT2467136E (pt) * 2009-12-07 2014-08-26 Raptor Therapeutics Inc Formulações de 4-metilpirazol
CA2808680A1 (en) * 2010-08-24 2012-03-01 The Regents Of The University Of California Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
FI128082B (en) * 2014-09-15 2019-09-13 Biohit Oyj Preparations for the treatment and prevention of alcohol redness and alcohol-induced hypersensitivity reactions
EP3323412A1 (en) * 2016-11-17 2018-05-23 Amalicon Holding AG Formulation comprising 4-methylpyrazole

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240069129A (ko) 2022-11-11 2024-05-20 대한민국(질병관리청 국립보건연구원장) 이상지질혈증 예측 또는 진단용 snp 마커 및 이의 용도
KR20240074388A (ko) 2022-11-21 2024-05-28 대한민국(질병관리청 국립보건연구원장) 당뇨병 예측 또는 진단용 hectd4 snp 마커 및 이의 용도

Also Published As

Publication number Publication date
JP2022536408A (ja) 2022-08-15
EP3973030A1 (en) 2022-03-30
JP2025093991A (ja) 2025-06-24
WO2020237172A1 (en) 2020-11-26
EP3973030A4 (en) 2023-05-31
TW202110437A (zh) 2021-03-16
US20220226286A1 (en) 2022-07-21
CN119909065A (zh) 2025-05-02
CN114144493A (zh) 2022-03-04

Similar Documents

Publication Publication Date Title
US20190231766A1 (en) Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
US9925174B2 (en) Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
JP2025093991A (ja) アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法
US20230133629A1 (en) Palatable compositions including sodium phenylbutyrate and uses thereof
CN1313769A (zh) 含有COX-2抑制剂和iNOS抑制剂的药物组合
EA016683B1 (ru) Фармацевтический препарат для перорального введения с контролируемым высвобождением активного ингредиента в тонком кишечнике и способ его получения
JP7266616B2 (ja) 糖尿病の治療において使用するためのトリアジン誘導体を含むフィルムコーティング錠剤
AU2020274165A1 (en) Compound for treating gout or hyperuricemia
WO2005097132A2 (en) Methods of treatment using eszopiclone
EP4304574A1 (en) Endoxifen for treatment of ovarian cancer
JP5101306B2 (ja) 糖尿病治療剤
CN111920811A (zh) 一种治疗抗痛风、抗高尿酸血症的药物组合物ⅲ
KR20170052688A (ko) 알코올 홍조 및 알코올-유발성 과민 반응의 치료 및 예방을 위한 제제
US20140030329A1 (en) Methods for Treating Insomnia
US20220031636A1 (en) Compounds that enhance the action of metformin
JP2024540241A (ja) 治療上の使用のためのアンブロキソールの修飾形態
CA2973944C (en) Solid composition of pyrrole carboxamide
JP2012219075A (ja) ナフトピジルを含有する医薬

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20211222

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20230522

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20250701

WITB Written withdrawal of application